問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2394Cases

2019-07-04 - 2022-05-31

Phase II

Completed
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Elsubrutinib, Upadacitinib

Participate Sites
6Sites

Recruiting6Sites

2023-02-01 - 2024-08-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2018-01-01 - 2023-05-12

Phase II/III

Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Risankizumab

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2023-09-01 - 2027-04-30

Phase II

Active
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Budigalimab (ABBV-181)；Livmoniplimab (ABBV-151)

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2017-12-21 - 2020-04-01

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Risankizumab(ABBV-066)

Participate Sites
6Sites

Recruiting5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2025-10-01 - 2030-12-24

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-07-01 - 2024-09-20

Phase III

Completed
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, with an Additional 18-Week Blinded Extension Period

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Cariprazine

Participate Sites
16Sites

Not yet recruiting3Sites

Recruiting11Sites

Terminated2Sites

2024-01-01 - 2030-11-30

Phase II/III

Active
A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment –LIVIGNO-2

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Livmoniplimab (ABBV-151)；Budigalimab (ABBV-181)

Participate Sites
5Sites

Recruiting5Sites

2024-12-01 - 2028-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine

  • Condition/Disease

    Menstrual Migraine (MM)

  • Test Drug

    NA

Participate Sites
5Sites

Recruiting5Sites

2025-05-01 - 2028-07-31

Phase II

Active
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Subjects with Metastatic Colorectal Cancer (AndroMETa-CRC-533)

  • Condition/Disease

    Metastatic colorectal cancer (mCRC)

  • Test Drug

    ABBV-400

Participate Sites
6Sites

Recruiting6Sites

1 35 36 37 38 39 240
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB